Loading
companiesCompany
Foresight Diagnostics
Stanford spin-out whose PhasED-Seq ctDNA technology detects residual lymphoma more accurately than PET/CT; clinical launch of CLARITY in 2026.
Overview
Foresight CLARITY uses phased variants on single cfDNA fragments to reach parts-per-million sensitivity. A pooled JCO analysis showed end-of-therapy MRD outperforms PET/CT in large B-cell lymphoma; SHORTEN-ctDNA (Columbia) tests MRD-guided chemotherapy de-escalation; a Hodgkin lymphoma MRD-guided trial launched 2026.
Similar pages
- CompanyPersonalis (Tempus)
Shares Push residual disease detection a hundredfold deeper with whole-genome methods, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaRead the spinal fluid to track brain tumours without opening the skull
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyNatera
Shares Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL, Reference materials and open proficiency testing for residual disease tests, Continuous and near-continuous ctDNA monitoring, Dormant cells and minimal residual disease.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- TechnologycfDNA fragmentomics
Shares Push residual disease detection a hundredfold deeper with whole-genome methods, Continuous and near-continuous ctDNA monitoring, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- TrialMERMAID-2
Shares Continuous and near-continuous ctDNA monitoring, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBlock the recycling that keeps dormant cells alive
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyAdaptive Biotechnologies
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.